Ultrasound-guided versus anatomic landmark-guided vascular access in cardiac electrophysiology procedures: A systematic review and meta-analysis

Konstantinos Triantafyllou a, *, Christos D. Karkos b, Nikolaos Fragakis a, Antonios P. Antoniadis a, Magdalini Meletidou a, Vassilios Vassiliou a

a 3rd Cardiology Department, Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Greece
b Vascular Unit, 5th Surgery Department, Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Greece

A R T I C L E   I N F O

Article history:
Received 8 October 2021
Received in revised form 21 December 2021
Accepted 25 January 2022
Available online 7 February 2022

Keywords:
Ultrasound
Vascular access
Catheter ablation
Electrophysiology
Complication

A B S T R A C T

Introduction: Electrophysiology (EP) procedures are nowadays the gold-standard method for tachyarrhythmia treatment with impressive success rates, but also with a considerable risk of complications, mainly vascular. A systematic review and meta-analysis was performed to evaluate the safety of ultrasound (US)-guided femoral vein access in EP procedures compared to the traditional anatomic landmark-guided method.

Methods: We searched Pubmed (MEDLINE), Embase, Web of Science, and Cochrane electronic databases for relevant entries, dated from January 1st, 2000 to June 30th, 2021. Only observational studies and randomized controlled trials were included in this analysis. Data extraction included study details, patient characteristics, procedure details, and all types of vascular complications. Complications were classified as major if any intervention, prolongation of hospitalization, or readmission was required.

Results: 9 studies (1 randomized controlled trial and 8 observational), with 7858 participants (3743 in the US-guided group, 4115 in the control group), were included in the meta-analysis. Overall vascular complication rates were significantly decreased in the US-guided group compared to the control group (1.2 versus 3.2%, RR = 0.38, 95% CI, 0.27–0.53), in all EP procedures. Sub-group analysis of AF ablation procedures yielded similar results (RR 0.41, 95% CI, 0.29–0.58, p < 0.00001). The event reduction effect was significant for both major and minor vascular complications.

Conclusion: US-guided vascular access in EP procedures is associated with significantly reduced vascular complications, compared to the standard anatomic landmark-guided approach, regardless of procedure complexity.

© 2022 Indian Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Electrophysiology (EP) procedures are currently the cornerstone of tachyarrhythmia treatment, with remarkable success rates. It is estimated that almost 300,000 catheter ablations are performed in Europe annually [1]. However, despite the continuous implementation of cutting-edge technologies, these procedures still have a considerable risk of complications. Among them, vascular access-related complications, including hematomas, bleeding, pseudoaneurysms, arteriovenous fistulas, and retroperitoneal hematomas, are the most common and have been associated with increased risk of morbidity, mortality, and health-care costs.

Several studies have shown the feasibility, efficacy and safety of ultrasound (US) guidance for femoral vascular access, compared to the traditional anatomic landmark-guided (ie. symphysis pubis and anterior superior iliac spine, inguinal ligament and femoral artery impulse) approach, in various patient groups. The US-guided method improves first pass and overall success rates, shortens time to successful cannulation and minimizes the risk of vascular complications [2–4].

This technique has been adopted as standard practice by several medical specialties, such as anesthetists, emergency physicians, critical care professionals, nephrologists, and pediatricians [5]. However, the majority of electrophysiologists still seem to prefer...
the conventional method. Evidence on US-guided vascular access in EP procedures emerged during the last decade with encouraging results. Safe vascular access is particularly important during ablation procedures for atrial fibrillation where multiple sizeable introducers are often used, patients are in uninterrupted anticoagulation and same-day discharge is aimed. Furthermore, arterial access, for the ablation of ventricular arrhythmias and retrograde approach for accessory pathway ablation, is safer with the use of US, especially in obese patients with poorly palpable femoral arteries or in cases where the femoral vein lies below the femoral artery. However, it is not yet considered as a standard of care in such procedures and has not gained universal application, mainly due to cost and training issues.

The objective of this meta-analysis is to review the recently published data and assess whether femoral vein cannulation under US guidance decreases the risk of vascular complications in EP procedures.

2. Methods

The study was conducted according to PRISMA guidelines. A comprehensive literature search of Pubmed (MEDLINE), Embase, Web of Science, and Cochrane electronic databases was conducted for the identification of relevant entries. We used the keyword string ‘ultrasound’ and ‘femoral’ or ‘vascular’ and ‘electrophysiology’ or ‘electrophysiological’ or ‘catheter ablation’ (Supplementary Table S1). Date filter was applied to include publications from January 1st, 2000 to June 30th, 2021. No language restrictions were applied.

We included prospective and retrospective observational studies and randomized controlled trials (RCTs), which compared the vascular complication rates of the US-guided versus the conventional anatomic landmark-guided technique for percutaneous femoral vein access during any EP procedures. Conference abstracts were not eligible. Two independent reviewers screened the titles and abstracts of the identified reports. The full texts of all potentially relevant papers were then assessed for inclusion in the analysis. Discrepancies were resolved by consensus.

Data extraction included publication details (publication year, authors, countries of origin), study design, enrollment period, inclusion/exclusion criteria, sample size, patient characteristics (age, gender, body weight index, use of antiplatelet and anticoagulant agents before the procedure) and procedure details (type of procedure, puncture needle size, periprocedural anticoagulant administration, vascular access time, first pass success rate, inadvertent arterial puncture, total procedure time, types and rates of vascular complications). The total number of vascular complications was the primary outcome. Secondary outcomes were: i. major vascular complications, ii. minor vascular complications, iii. inadvertent arterial punctures, iv. total vascular complications in atrial fibrillation (AF) ablation procedures. Vascular complications were classified as major in case of a clinically overt hematoma, bleeding, arteriovenous fistula, pseudoaneurysm, or retroperitoneal hematoma, and required intervention (percutaneous thrombin injection, surgical repair, blood transfusion), prolonged hospitalization, or readmission. All other complications were classified as minor.

We used Review Manager Version 5.4 and R Version 4.0.2 software for statistical analysis. A random-effects model (Mantel-Haenszel method) was selected for the calculation of pooled intervention effects on dichotomous outcomes. Risk ratios (RR) with 95% confidence intervals (CI) were measured and a two-sided p-value <0.05 on the z-test was considered statistically significant. We also estimated the numbers needed to treat (NNT), deriving from total and major event rates. Forest plots for each intervention effect outline the statistical results. Heterogeneity between studies was assessed by visual inspection of the forest plots and calculation of $\chi^2$ heterogeneity statistic tests. Heterogeneity was also considered substantial if the p-value was <0.10 in the chi-square test and if the $I^2$ statistic exceeded 50%. Sensitivity analysis was performed to assess the impact of anticoagulation strategy during catheter ablation procedures on the pooled estimate of the vascular complication rates and the heterogeneity across studies. Meta-regression analysis was conducted for the assessment of the impact of mean body mass index (BMI) in the studies on total complication rates. Data were also processed in a sub-group analysis, based on the study design. A funnel plot was created for publication bias assessment. Risk of bias was assessed using the Revised Cochrane risk of bias tool for randomized trials (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions tool (ROBINS-I) [6,7].

3. Results

The outline of the study selection process is depicted in a PRISMA diagram (Fig. 1). Initial electronic database screening

![Fig. 1. Study flow diagram.](image-url)
Table 1
Basic characteristics of the studies included in the analysis.

| 1st author       | Year | Country | Design                                      | Enrollment period | EP Procedures | Redo (%) | Sample size (US/non-US) | Age (mean ± SD) | Male (%) | BMI (mean ± SD) | Periprocedural anticoagulation status | Protamine use (%) | Puncture time (sec) | Procedure time (min) |
|-------------------|------|---------|---------------------------------------------|-------------------|---------------|-----------|------------------------|----------------|----------|----------------|----------------------------------------|-------------------|---------------------|---------------------|
| Tanaka-           | 2013 | USA     | Single-center, observational, retrospective cohort | January 2005–December 2006 | AF ablation | NR        | 3420 (1511/1909)       | NR 77.6         | NR       | 100            | 100                                    | NR                | US                  | non-US              |
| Esposito          |      |         |                                             |                   |               |           |                        |                |          |                |                                        |                   |                     |                     |
| Errahmouni        | 2014 | Monaco  | Single center, observational, retrospective cohort | April 2012–October 2012 | All EP procedures | NR        | 300 (150/150)          | 64.6 ± 17       | 65.3     | 28.2 ± 4.5     | UI                                     | 100               | 280 ± 151           | NR                  |
| Wynn              | 2014 | UK      | Single-center, observational, prospective cohort | May 2012–September 2012 | AF ablation | NR        | 309 (163/146)        | 58.9 ± 10.2     | 72.5     | 29.6 ± 4.6     | UI                                     | 88.3              | NR                  |                     |
| Rodriguez-Kuyz     | 2015 | Spain   | Single-center, observational, prospective cohort | October 2012–February 2013 | All EP procedures | NR        | 36 (24/12)            | 63.9 ± 19.4     | 69.4     | 26.0 ± 4.6     | NR                                     | NR                | 87.3 ± 94.3          | 120 [46.0–422.0] |
| Sharma            | 2016 | USA     | Single-center, observational, prospective cohort | October 2014–May 2015 | All EP procedures | NR        | 720 (360/360)         | 57.9 ± 16       | 53.0     | 30.0 ± 7.0     | UI                                     | NR                | 369 [257–584]        | NR                  |
| Yamagata          | 2017 | Czech Republic, Japan | Multi-center (4 centers), randomized controlled trial | March 2016–November 2016 | AF ablation | 37        | 319 (159/160)         | 63.0 ± 8        | 61.4     | 29.6 ± 5.2     | UI                                     | 63.6              | 288 [191–370]        | NR                  |
| Ströker           | 2018 | Belgium | Multi-center (2 centers), observational cohort | June 2012–August 2016 | AF ablation | 0         | 1435 (300/1135)       | 60.0 ± 12.0     | 65.1     | 27.0 ± 4.0     | UI                                     | NR                | 60 ± 18              | 79 ± 27             |
| Futyma            | 2019 | Poland  | Single-center, observational cohort | November 2016–April 2019 | All EP procedures | NR        | 981 (876/105)        | 55.5 ± 16.5     | 45.2     | 28 ± 5.5       | NR                                     | NR                | NR                  | NR                  |
| La Greca          | 2020 | Italy   | Single-center, observational, retrospective cohort | January 2010–March 2016 | AF ablation | 20        | 374 (224/150)        | 60 ± 6          | 74       | 27 ± 3         | UI                                     | 0                 | NR                  | 180 ± 30            |

AF: atrial fibrillation, BMI: body mass index, CTI: cavotricuspid isthmus, EP: electrophysiology, I: interrupted, non-US: non-ultrasound group, NR: not reported, UI: uninterrupted, US: ultrasound group.
identified 587 records. Of them, 570 articles were excluded, due to duplication, not relevance, or not meeting the inclusion criteria. We assessed 17 full-text studies for eligibility. Six congress abstracts, 1 single-arm study, and 1 study not meeting the outcome definitions were excluded. Finally, 9 studies were included in the meta-analysis: 1 RCT and 8 observational cohort studies (3 prospective, 3 retrospective, 2 not specified) [8–16]. The basic study characteristics are summarized in Table 1. Five studies included only AF catheter ablation procedures while 4 studies included all EP procedures. The sample size for each study ranged from 36 to 3420 participants and the summed study population for the analysis was 7858 patients; 3743 in the US (intervention) group and 4115 in the non-US (control) group.

The total number of vascular complications in both groups was reported in 8 studies. US-guided group had a significantly decreased incidence of total vascular complications compared to non-US-guided group (1.2 versus 3.2%, RR = 0.38, 95% CI, 0.27–0.53, \( p < 0.00001 \), Fig. 2). The rate of major vascular complications (Table 2) was also reduced in the US group (0.7% versus 2%, RR = 0.38, 95% CI, 0.25–0.59, \( p < 0.0001 \), Fig. 3). NNT were estimated to be 50 and 80 for all and major vascular events respectively. Similar findings resulted from the analysis for minor vascular complications (Table 3) (RR = 0.38, 95% CI, 0.22–0.59, \( p < 0.0004 \), Fig. 4). All tests for heterogeneity were not significant and the studies were homogenous for overall, major and minor vascular complication outcomes. Meta-regression analysis showed mean BMI did not significantly affect total vascular complications in the studies included (\( p\)-value 0.97) (Fig. 5). In the sub-group analysis based on the study design, the results for total vascular complications were similar for both prospective and retrospective observational cohort studies (Fig. 6). In the funnel plot, including 8 studies for the outcome of total vascular complications, an asymmetry in the scatter of small studies can be observed (Fig. 7). The risk of bias for each study in individual domains as well as the

### Table 2

Major vascular complications in the studies included in the analysis.

| Study or Subgroup | US-guided | Conventional | Risk Ratio |
|-------------------|-----------|--------------|------------|
|                   | Events    | Total        | M-H, Random, 95% CI |
| US nonUS          | Events    | Total        | M-H, Random, 95% CI |
|                   |           |              | Year       |
| US                | nonUS    | US            | nonUS     | US       | nonUS    | US       | nonUS    | US       | nonUS    |
| US nonUS          | Events    | Total        | M-H, Random, 95% CI |
|                   | Events    | Total        | M-H, Random, 95% CI |
|                   |           |              | Year       |
| Total (95% CI)    | 3743      | 4115         | 100.0%     | 0.38 [0.27, 0.53] |
| US nonUS          | Total     | Homatoma or bleeding | |
|                   | Events    | Total        | M-H, Random, 95% CI |
|                   | Events    | Total        | M-H, Random, 95% CI |
|                   |           |              | Year       |
| Total (95% CI)    | 3743      | 4115         | 100.0%     | 0.38 [0.27, 0.53] |

**Fig. 2.** Forest plot of comparison: US-guided vs. Conventional, outcome: Total vascular complications.

**Fig. 3.** Forest plot of comparison: US-guided vs. Conventional, outcome: Major vascular complications.
overall estimates are reported in Table 4. Low risk of bias was estimated for the RCT, whereas 7 observational cohort studies were at moderate and one at serious risk of bias, reflecting the inherent weaknesses of this study category.

For the outcome of inadvertent arterial puncture, there was a relative risk reduction by 76% in the US group compared to the non-US group (2.4% versus 17%, Fig. 8). I² was measured 50% for this outcome, rendering a moderate heterogeneity of the studies. Five studies included only AF ablation procedures, whereas another one provided data for this patient subgroup. When the analysis was restricted to these studies, we estimated a similar RR reduction, again in favor of the US group (0.41, 95% CI, 0.29–0.58, p < 0.00001, Fig. 9).

4. Discussion

To our knowledge, this is the largest meta-analysis published for this subject, including only RCTs and observational studies. We found a significant risk reduction by 62% for vascular complications for the US-guided femoral venipuncture, compared to the conventional, anatomic landmark-guided technique. The estimated NNT indicate that the adoption of routine use of US for venous access in EP procedures could prevent a considerable number of vascular complications with a potential beneficial impact on morbidity, hospital stay length, and total costs, especially in high volume EP centers.

Our findings keep in line with the results of a previous meta-analysis, which included 4 observational only trials with 4605 patients and showed 60% and 66% relative risk reduction in major and minor vascular complications respectively [17]. Only one RCT has been conducted in this specific field till date [13]. It enrolled 320 patients who underwent catheter ablation for AF, randomized in a 1:1 fashion. The study failed to demonstrate a difference in major vascular complication rates between the two arms and was prematurely terminated due to lower-than-expected events. An additional contributing factor to the neutral study result was the
considerable cross-over rate (9%) from the conventional to the US group. However, several secondary intra-procedural parameters were in favor of US guidance, irrespective of operator experience.

The rate of vascular complications during catheter ablation procedures in our study population remains within the ranges of previously published reports [18]. Of note, Wynn et al. found a remarkably high number of major complications, while Yamagata et al. reported a quite frequent rate of inadvertent arterial punctures. The origins of these discrepancies are uncertain, but they likely did not impact the outcomes of the meta-analysis as random effects models were employed. Among EP procedures, AF and ventricular tachycardia ablations have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12]. This occurs mainly due to multiple and large sheath insertions as well as uninterrupted peri-procedural anticoagulation, which have a higher incidence of femoral access complications [12].
Table 4
Risk of bias assessment.

| Study        | D1 | D2 | D3 | D4 | D5 | Overall |
|--------------|----|----|----|----|----|---------|
| Yamagata 2018 | +  | +  | +  | +  | +  | +       |

Domains:

D1: Bias arising from the randomization process.

D2: Bias due to deviations from intended intervention.

D3: Bias due to missing outcome data.

D4: Bias in measurement of the outcome.

D5: Bias in selection of the reported result.

Judgement:

Low

[Table showing risk of bias domains for different studies with ratings of Low, Moderate, and Serious]

Domains:

D1: Bias due to confounding.

D2: Bias due to selection of participants.

D3: Bias in classification of interventions.

D4: Bias due to deviations from intended interventions.

D5: Bias due to missing data.

D6: Bias in measurement of outcomes.

D7: Bias in selection of the reported result.

Judgement:

Serious

Moderate

Low
variations, which cannot be predicted if no imaging method is used. Inadvertent arterial puncture, even not considered as a vascular complication itself, may potentially predispose to severe clinical adverse events, especially in cases of uninterrupted anticoagulation.

Various US devices are currently widely available and have been used in the studies (Table 5). Rodriguez Munoz et al. used a wireless linear array US probe, which is probably more convenient for the operator and facilitates the preservation of sterile conditions during the procedure [11].

Valsalva maneuver (VM) increases peripheral venous pressure and the diameter of the femoral vein [24]. Futyma et al. assessed the effectiveness of this technique during US-guided femoral vein punctures in EP procedures [15]. No significant differences in the rates of minor or major adverse events between the VM-supported and standard methods were observed, probably due to the low number of events. However, VM seemed to facilitate venous access and a trend towards a lower incidence of vascular complications was noted. It was suggested that VM can be also performed with the traditional anatomic landmark-guided technique. Moreover, it could be beneficial especially in patients who have anatomical abnormalities or small femoral vein diameters, such as women and underweight individuals.

Puncture needle size was reported in only 3 of the studies included, in which a 18-G (gauge) needle was used. However, there is evidence to support that introduction of a micropuncture needle (21-G) in combination with US guidance could potentially further reduce vascular access complications, especially in the high-risk anticoagulated patients [25–27].

Generally, physicians do not perform venipuncture under US guidance. Lack of equipment, time consumption, and insufficient training are the most frequently reported limiting factors [28]. However, US-guided femoral puncture in EP procedures has a rather easy learning curve and does not interfere with the normal workflow [29]. It is estimated that only six to seven cases are needed for operators to reach the beginning of puncture time plateau. Moreover, no difference in puncture times was found between senior operators and fellows [9]. No study about the financial evaluation of the technique has ever been performed. However, an economic analysis estimated an additional cost of less than £10 per procedure. It was also concluded that the implementation of US devices is in the long term cost-effective due to reduced complications [30].

Real-time US-guided venipuncture is currently recommended for patients undergoing AF ablation and/or electrophysiological procedures by international EP societies as a safer, faster, and more effective technique [19]. However, this method has not yet been widely adopted by electrophysiologists and only a minority uses vascular US devices in the EP lab routinely. We believe that this meta-analysis offers robust data which can influence the current clinical practice.

### 4.1. Limitations

Firstly, only one randomized study was included in the analysis. The majority of data was extracted from observational studies, which forms a potential source of bias. These studies have been conducted in large volume centers with high level of operator expertise, which led to limited number of complications. However,
the lack of heterogeneity between studies and the high level of significance indicate unbiased results. Nevertheless, a large randomised prospective study would probably be needed to provide adequate number of data points and show a robust difference between the two techniques. Secondly, the definitions used for the classification and severity of vascular complications were not universal and minor discrepancies between studies may exist. Thirdly, subgroup analyses based on patient and procedure characteristics were not performed, since patient-level data were not available. Fourthly, publication bias cannot be adequately estimated, since only 8 studies were used for the analysis.

5. Conclusions

US-guided vascular access in EP procedures is associated with significantly reduced vascular complications, compared to the standard anatomic landmark-guided approach. Based on these findings, routine use of US-guidance for femoral vein cannulation should be considered and US devices may become part of the standard EP lab equipment.

Funding

None.

CRediT author statement

Konstantinos Triantafyllou: Conceptualization, Methodology, Formal analysis, Investigation, Writing - Original Draft. Christos D Karkos: Conceptualization, Methodology, Formal analysis, Investigation, Writing - Original Draft. Nikolaos Fragakis: Methodology, Writing - Original Draft, Supervision. Antonios P Antoniadis: Writing - Review & Editing, Visualization. Meletidou Magdalini: Writing - Review & Editing, Visualization. Vassilios Vassilikos: Conceptualization, Writing - Review & Editing, Supervision.

Declaration of competing interest

The authors have no potential conflicts of interest to disclose.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpae.2022.01.005.

References

[1] Rautakari MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, et al. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European society of cardiology countries: 2017 report from the European heart rhythm association, European 2017;19:i1–90.
[2] Prabhu MV, Junjea D, Gopal PB, Sthanarayanan M, Subramaniam S, Gandhe S, et al. Ultrasound-guided femoral dialysis access placement: a single-center randomized trial. Clin J Am Soc Nephrol 2010;5:235–9.
[3] Braas P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catherization. Cochrane Database Syst Rev 2015;1:CD011447.
[4] Reusz C, Csomos A. The role of ultrasound guidance for vascular access. Curr Opin Anaesthesiol 2015;28:710–6.
[5] Lamperti M, Bodenham AR, Pittiruti M, Blavas M, Augoustides JG, Elbarbary M, et al. International evidence-based recommendations on ultrasound-guided vascular access. Intensive Care Med 2012;38:1105–17.
[6] Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Burton I, et al. ROB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:14898.
[7] Sterne JAC, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 2016;355:j4919.
[8] Tanaka-Exposito CC, Chung MK, Abraham JM, Cantillon DJ, Abi-Saleh B, Tchou PJ. Real-time ultrasound guidance reduces total and major vascular complications in patients undergoing pulmonary vein isolation on therapeutic warfarin. J Interv Card Electrophysiol 2013;37:163–8.
[9] Errahmouni A, Bunn SS, Latcu DG, Saoudi N. Ultrasound-guided venous puncture in electrophysiological procedures: a safe method, rapidly learned. Pacing Clin Electrophysiol 2014;37:1023–8.
[10] Wynn GJ, Haq I, Hung J, Bonnett LJ, Lewis G, Webber M, et al. Improving safety in catheter ablation for atrial fibrillation: a prospective study of the use of ultrasound to guide vascular access. J Cardiovasc Electrophysiol 2014;25:680–5.
[11] Rodríguez Muñoz D, Franco Diez E, Moreno J, Lumia G, Carbonell San Román A, Segura De La Ca T, et al. Wireless ultrasound guidance for femoral venous cannulation in electrophysiology: impact on safety, efficacy, and procedural delay. Pacing Clin Electrophysiol 2015;38:1058–65.
[12] Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016;27:1169–76.
[13] Yamagata K, Wichterle D, Roubleck T, Jarkovsky P, Sato Y, Kogure T, et al. Ultrasound-guided versus conventional femoral venous puncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-PAST trial). Europace 2018;20:1107–14.
[14] Ströker E, de Asmundis C, Kupics K, Takara K, Mugnai G, De Cock J, et al. Value of ultrasound for access guidance and detection of subclinical vascular complications in the setting of atrial fibrillation cryoballoon ablation. Euro- pace 2019;21:434–9.
[15] Futyma P, Cappato K, Sander J, Guszczyck R, Futyma M, Kubkowski P. Ultrasound-guided venous access facilitated by the Valsalva maneuver during invasive electrophysiological procedures. Kardiol Pol 2020;78:123–8.
[16] La Greca C, Girasol A, Di Modica D, Sorgato A, Simoncelli U, Pecora D. Advantages of the integration of ICE and 3D electroanatomical mapping and ultrasound-guided femoral venous puncture in catheter ablation of atrial fibrillation. J Intervent Card Electrophysiol 2021;61:559–66.
[17] Sobolev M, Shiloh AL, Di Base L, Slovot DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace 2017;19:850–5.
[18] Hindricks G, Potpara T, Dgres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. 2020 Eur Heart J 2020;42:373–498.
[19] Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinauma L, et al. HRS/EHRA/ECAS/APHRS/SOLACE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2017;20:61–160. 2018.
[20] Basu-Ray I, Khanna D, Kupo P, Bunch J, Theus SA, Mulherjee A, et al. Outcomes of uninterrupted vs interrupted periprocedural direct oral anticoagulants in atrial fibrillation ablation: a meta-analysis. J Arrhythm 2021;37(2):384–93. Jan 29.
[21] Sherev DA, Shaw RE, Brent BN. Angiographic predictors of femoral access site complications: implication for planned percutaneous coronary intervention. Cathet Cardiovasc Interv 2005;65:196–202.
[22] Hughes P, Scott C, Bodenham A. Ultrasonography of the femoral vessels in the groin: implications for vascular access. Anaesthesia 2000;55:1198–202.
[23] Baum PA, Matsunoto AH, Teitelbaum GP, Zuurbier RA, Barth KH. Anatomic relationship between the common femoral artery and vein: CT evaluation and clinical significance. Radiology 1989;173:775–7.
[24] Porth CJ, Bamrah VS, Tristan FE, Smith JJ. The Valsalva maneuver: mechanisms and clinical implications. Heart Lung 1984;13:507–18.
[25] Ng C, Rozen G, Biton Y, Leyton-Mange J, Barrett C. Direct ultrasound visualization in combination with micropuncture needle reduces vascular access complications in cardiac electrophysiological procedures. European 2017;19:1171–7.
[26] Dussault G, Baldinger S, Tedrow UB, Michaud G, Koplan B, Stevenson W. Preventing vascular access complications for ablation on uninterrupted anticoagulants in atrial Fibrillation ablation: a meta-analysis. J Arrhythm 2021;37(2):384–93. Jan 29.
[27] Buchanan MS, Backlund B, Liao MM, Sun J, Cydulka RK, Smith-Coggins R, et al. Improved safety, efficacy, and procedural outcomes when using a vascular ultrasound device to guide vascular access during therapeutic warfarin. J Intervent Card Electrophysiol 2012;31:1493–8.
[28] Buchanan MS, Backlund B, Liao MM, Sun J, Cydulka RK, Smith-Coggins R, et al. Use of ultrasound guidance for central venous access and imaging during transvenous ablation of atrial fibrillation. J Intervent Card Electrophysiol 2014;40:53–60.
[29] Boudreault SP, Moayyedi S, Boucher S, Elhassan M, Tabban A, Bhatt P, et al. Ultrasound-guided venous access using ultrasound guidance and the Valsalva maneuver for catheter ablation. J Intervent Card Electrophysiol 2013;32:295–300.
[30] National Institute for Health and Care Excellence. Guidance on the use of ultrasound locating devices for placing central venous catheters. NICE Technolne appraisal guidance [TA49]. 2002. https://www.nice.org.uk/guidance/ta49.